Susquehanna International Group, LLP Travere Therapeutics, Inc. Transaction History
Susquehanna International Group, LLP
- $560 Billion
- Q3 2024
A detailed history of Susquehanna International Group, LLP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 38,297 shares of TVTX stock, worth $703,515. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,297
Previous 104,748
63.44%
Holding current value
$703,515
Previous $861,000
37.86%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding TVTX
# of Institutions
193Shares Held
83.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$140 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$140 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$127 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$86.1 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$79.7 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.18B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...